...
【24h】

Oxalic Acid as a uremic toxin.

机译:草酸作为尿毒症毒素。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Oxalic acid (OA) is thought to be a uremic toxin that participates in the pathogenesis of uremic syndrome. The objectives of this study were to: (1) evaluate the plasma levels of OA in patients with chronic renal disease with various levels of glomerular filtration rate and after renal transplantation; (2) investigate the salivary secretion of OA and ascorbic acid in healthy subjects and in patients with chronic renal failure (CRF); (3) examine the influence of water and sodium diuresis and furosemide administration on the urinary excretion of OA and ascorbic acid in healthy subjects and in CRF patients without dialysis treatment; and (4) evaluate the influence of renal replacement therapy (RRT) on secondary hyperoxalemia in hemodialysis patients. DESIGN AND SETTING: This study was conducted at the Nephrological Department of P.J. Safarik University. Sixty-one patients with chronic renal disease, 64 CRF patients, 32 continuous ambulatory peritoneal dialysis (CAPD) patients, 15 hemodialysis patients, 21 patients after renal transplantation, and 15 healthy subjects were examined. Maximal water diuresis, diets with low (2 g/day) and high (15 g/day) sodium intake, administration of intravenous furosemide (20 mg), and renal replacement therapy (CAPD, hemodialysis, hemofiltration, and postdilution hemodiafiltration) were utilized in the study. RESULTS: In patients with chronic renal disease and those after renal transplantation, direct relationships between plasma OA and serum creatinine were found (r = 0.904 and 0.9431, respectively, P < .01). Despite a high level of plasma OA in uremic patients (23.1 +/- 10 micromol/L), there was no significant difference in salivary OA between control subjects (128 +/- 19 micromol/L) and CRF patients (135 +/- 24 micromol/L). The urinary excretion of OA during maximal water diuresis (from 37.5 to 110.3 micromol/4 hours) and after intravenous furosemide (from 34.5 to 66.7 micromol/3 hours) increased significantly, but was not affected by high intake of NaCl. The most significant decrease of plasma OA was observed during postdilution hemodiafiltration (63.3%). CONCLUSION: Our study indicates that renal replacement therapy is not effective for a permanent reduction of elevated plasma levels of OA.
机译:目的:草酸(OA)被认为是尿毒症毒素,参与尿毒症综合征的发病机理。这项研究的目的是:(1)评价具有不同肾小球滤过率水平的慢性肾脏病患者和肾移植后的血浆OA水平; (2)调查健康受试者和慢性肾功能衰竭(CRF)患者唾液中OA和抗坏血酸的分泌; (3)检查健康受试者和未经透析治疗的CRF患者中水和利尿钠及速尿对尿中OA和抗坏血酸排泄的影响; (4)评估肾脏替代疗法(RRT)对血液透析患者继发性高氧血症的影响。设计与地点:这项研究是在P.J. Safarik大学肾脏科进行的。检查了61例慢性肾脏病患者,64例CRF患者,32例持续性非卧床腹膜透析(CAPD)患者,15例血液透析患者,21例肾移植后患者和15例健康受试者。使用最大的水利尿,低钠摄入量(2 g /天)和高钠摄入量(15 g /天),静脉注射速尿(20 mg)和肾脏替代疗法(CAPD,血液透析,血液滤过和稀释后血液透析滤过)在研究中。结果:在患有慢性肾脏疾病和肾移植后的患者中,血浆OA和血清肌酐之间存在直接关系(r分别为0.904和0.9431,P <.01)。尽管尿毒症患者的血浆OA水平较高(23.1 +/- 10 micromol / L),但对照组(128 +/- 19 micromol / L)和CRF患者(135 +/-)的唾液OA没有显着差异。 24微摩尔/升)。在最大水利尿期间(从37.5到110.3 micromol / 4小时)和静脉注射速尿(从34.5到66.7 micromol / 3小时)后,OA的尿排泄显着增加,但不受高NaCl摄入量的影响。在稀释后血液透析滤过过程中,血浆OA的下降最为明显(63.3%)。结论:我们的研究表明,肾脏替代治疗不能永久降低血浆中OA水平升高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号